Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
Gulf Chronic Care, Inc. was established specifically to address the diabetic epide...
Gulf Chronic Care, Inc. was established specifi...
Kitov Pharma is an innovative biopharmaceutical drug development company. Leveragi...
Kitov Pharma is an innovative biopharmaceutical...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Join the National Investor Network and get the latest information with your interests in mind.